Method of diagnosing vascular dementias and acute cerebral ischemia

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a diagnostic method for identifying vascular dementias or acute cerebral ischemia (stroke) by measuring the concentration of specific amyloid-beta (Aβ) peptide species in a patient's blood sample. By comparing the levels of certain Aβ peptides, such as Aβ1-37, Aβ1-38, Aβ1-39, Aβ1-42, and Aβ2-40, to established threshold values, clinicians can distinguish between vascular dementia, Alzheimer's disease, depression, and acute stroke through a minimally invasive blood test.

Use CasesContent extracted from patent full text and abstract with AI.

• Early diagnosis of vascular dementia in at-risk patients via blood analysis.
• Rapid differential diagnosis between vascular dementia and Alzheimer's disease using biomarker thresholds.
• Diagnosis of acute cerebral ischemia (stroke) shortly after onset to enable timely intervention.
• Screening patients with cognitive impairment to determine the underlying vascular or neurodegenerative etiology.
• Use in research settings to study the progression and distinction of different dementias based on blood biomarkers.
• Monitoring patients with mild cognitive impairment for early detection of vascular changes.

BenefitsContent extracted from patent full text and abstract with AI.

• Minimally invasive diagnostic method (requiring only a blood sample) compared to cerebrospinal fluid collection.
• Provides high sensitivity and specificity for discriminating vascular dementia from Alzheimer's disease and other dementias.
• Enables early and rapid detection of acute cerebral ischemia, which is critical for positive patient outcomes.
• Facilitates more accurate diagnosis and appropriate treatment plans for patients with cognitive impairment.
• Can help avoid misdiagnosis and inappropriate therapies by distinguishing between various dementia types.
• Potential for automation and integration into clinical laboratory workflows for routine dementia screening.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

A method of diagnosing vascular dementias and acute stroke comprises the step of determining a concentration of at least one amyloid ² peptide species in a blood sample taken from a patient. The at least one amyloid ² peptide species is selected from the group consisting of A²1-37, A²1-38, A²1-39, A²1-42, and A²2-40. The concentration of the at least one amyloid ² peptide species is compared to a threshold value for the respective one amyloid ² peptide species; and a concentration of the least one amyloid ² peptide species beyond the threshold value for the respective one amyloid ² peptide species is taken as an indication of a vascular dementia or acute stroke in the patient from which the blood sample was taken.